Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 363 participants.

Also called NCT01630278

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 363 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01630278
Other papers using this trial's data
  • Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial The Journal of pediatrics, 2021-06 DOI, PubMed 33307111

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01630278. Randomized; quadruple masking; primary purpose treatment. Start 2012-03 (actual); primary completion 2019-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)
Acronym
TRIOCAPI
Condition
Patent Ductus Arteriosus
Intervention (Drug)
Ibuprofen
Intervention (Drug)
Placebo
Lead sponsor
Nantes University Hospital (class: other)

Record details

Record id
cardio:ct-nct01630278
Content hash
e608d4bb4824a20d90bc3883b3f274c321a0c6a0e2cd88022bf487fe0385a274